Other languages Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
27.64 ^USD	-8.26%		-13.19%	-12.34%

Mar. 27	Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	MT
Mar. 21	Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	Mar. 27
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	Mar. 07
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07
Arcturus Therapeutics Holdings Inc. Announces Executive Changes	Feb. 23
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	Feb. 22
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems	Jan. 05
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster	Dec. 21
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults	Nov. 28
Sector Update: Health Care Stocks Softer Monday Afternoon	Nov. 27
Arcturus Therapeutics Says FDA Grants Orphan Drug Designation for ARCT-032 to Treat Cystic Fibrosis	Nov. 27
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo	Nov. 27
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	Nov. 15
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges; Shares Soar Premarket	Nov. 15
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges	Nov. 14
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Arcturus Therapeutics Holdings Insider Sold Shares Worth $128,062, According to a Recent SEC Filing	23-10-04
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Wins Additional Financial Grants from Japanese Government	23-10-04
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA Therapeutic to Treat Cystic Fibrosis	23-09-26
Arcturus Says Phase 1/2 Trial of COVID-19 Booster Vaccine Shows Immune Response for 12 Months	23-09-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Other languages

Filters